[Place adjuvant targeted therapies during localized NSCLC]

Area of Science:

• Oncology
• Molecular Biology
• Thoracic Surgery

Background:

• Non-small cell lung cancer (NSCLC) patients with EGFR mutations or ALK rearrangements benefit from targeted therapies.
• Adjuvant treatment with tyrosine kinase inhibitors (TKIs) shows promise after surgical resection in specific NSCLC subtypes.
• Current guidelines recommend testing for these driver alterations.

Purpose of the Study:

• To highlight the benefit of adjuvant TKIs in EGFR-mutant and ALK-positive NSCLC.
• To emphasize the importance of molecular testing on surgical specimens and biopsies.
• To identify key areas for future research regarding TKI implementation.

Main Methods:

• Review of current clinical evidence and guidelines.
• Analysis of the role of molecular testing in NSCLC management.
• Identification of unresolved clinical questions.

Main Results:

• EGFR-mutant and ALK-positive NSCLC patients benefit from adjuvant TKI therapy post-complete resection.
• Testing for EGFR mutations and ALK positivity is crucial for guiding adjuvant treatment decisions.
• Key implementation questions include optimal treatment duration, management of recurrence, and impact on molecular evolution.

Conclusions:

• Adjuvant TKIs represent a valuable strategy for specific NSCLC patient groups.
• Standardized molecular testing is essential for identifying eligible patients.
• Further research is needed to address treatment duration, recurrence management, and molecular evolution in the context of adjuvant TKI therapy.